Upstate Active Clinical Trials
Study Title:Celldex Protocol CDX110-04: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
What is the purpose of the study?This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express the EGFRvIII protein) to the current standard of care (temozolomide) in patients with recently diagnosed glioblastoma, a type of brain cancer.
Upstate Institutional Review Board (IRB) Number:290794
Patient Age Group:Adults
Principal Investigator:Thomas E Coyle, MD
Who can I contact for more information?
Name: Diane M Gould